CBD and postpartum depression and baby blues: what does science say about safety

• WHO: about 13% of women after childbirth experience a mental disorder, most often depression; in developing countries, 19.8%.

KEY INFORMATION
• EFSA 2026: the safety of CBD cannot be established in breastfeeding women, individuals under 25 years of age, and those taking medications.
• In the milk of 50 women using marijuana, THC was detected in 63% of samples, cannabidiol only in 5 out of 54 (Bertrand et al., Pediatrics 2018).
• Postpartum depression is a condition treated with psychotherapy or pharmacotherapy, not a supplement.
The distinction determines what should be done. Baby blues is a temporary mood swing in the first days after childbirth, characterized by tearfulness, irritability, and anxiety, usually resolving before the end of the second week. It does not require treatment, but rather rest and support from the environment.

What is baby blues, and what is postpartum depression?

Postpartum depression is a clinical condition: a persistent low mood lasting more than two weeks with a loss of joy in motherhood, sleep disturbances unrelated to the child's needs, intrusive thoughts, and difficulty in care and bonding. It does not resolve on its own and requires intervention.

The scale is large and well-documented. The World Health Organization states that about 10% of pregnant women and about 13% of women who have just given birth experience a mental disorder, primarily depression, and in developing countries, these rates are 15.6% and 19.8%, respectively (

). The previous version of this article stated a range of 10-15% and referred to a link that now returns a 404 error, as well as attributing 50-80% of mothers to baby blues without citing a source. The number without a source has been removed from the text.WHO, zdrowie psychiczne matekDelaying help in the hope that it will "pass on its own" or that "a supplement will be enough" prolongs treatment and exacerbates the illness. This is the most important sentence of this article and stands here before any discussion about cannabinoids.

The most frequently cited measurement concerns women using marijuana, not women using cannabidiol preparations, and this distinction changes the meaning of the result. It is worth reading it carefully, as it circulates in a distorted version.

What does science say about CBD and breastfeeding?

Fifty breastfeeding women reporting marijuana use provided a total of 54 milk samples between 2014 and 2017. THC was detected in 34 samples, or 63%, up to about six days after the last reported use, with a median concentration of 9.47 ng/ml. Cannabidiol or 11-hydroxy-THC appeared in only five samples, with concentrations of cannabidiol ranging from 1.32 to 8.56 ng/ml. Cannabinol was not found in any sample.

W pracy Bertrand et al. (Pediatrics, 2018) Fifty breastfeeding women who reported using marijuana provided a total of 54 milk samples between 2014 and 2017. THC was detected in 34 samples, which is 63%, up to about six days after the last reported use, with a median concentration of 9.47 ng/ml. Cannabidiol or 11-hydroxy-THC appeared in only five samples, with cannabidiol concentrations ranging from 1.32 to 8.56 ng/ml. Cannabinol was not found in any sample.

The previous version of this article misrepresented this result in three ways at once. It stated that cannabidiol lasts for six days, while six days pertains to THC. It mentioned fifty women in the text, but twenty-five in the structural data. It also added that THC can last "up to six weeks," which is not present in this work. The identifier under which all of this stood led to an article about organometallic materials.

The proper precaution lies elsewhere. The update from the European Food Safety Authority (EFSA, panel NDA, 2026) states outright that the safety of cannabidiol cannot be established for breastfeeding women, for individuals under 25 years of age, and for those taking medications simultaneously. The latter group includes a significant portion of postpartum women.

Why does exposure of an infant to cannabinoids raise concerns?

The reason is the role of the endocannabinoid system in brain development, rather than measured harm to a specific child. Endocannabinoids are involved in the proliferation of neurons, their migration, synapse formation, and myelination, which are processes that occur most intensively in the first months of life.

Cannabinoids delivered from outside can interfere with this signaling. Whether the interference is neutral, beneficial, or harmful is unknown, as no one has measured this in infants. The EFSA position notes, however, that after prenatal exposure in animal models, long-term and sex-dependent neurodevelopmental effects have been observed, and no study has yet investigated the immunotoxicity of cannabidiol.

The clinical report of the American Academy of Pediatrics (Ryan i wsp., Pediatrics 2018) indicates the ability of cannabinoids to cross the placenta as a reason for concerns about both the course of pregnancy and distant consequences for the child, and separately refers to breastfeeding. This is a document about cannabis as a substance, not about cannabidiol itself, and it should be read as such.

It is worth mentioning something that is easily overlooked: the lack of data is not evidence of harm. It is, however, a reason not to take risks when there is treatment with a described safety profile. Such treatment exists for postpartum depression.

What really works for postpartum depression?

Postpartum depression is a treatable and well-researched condition, and the methods with the strongest evidence are psychological and pharmacological. None of them are supplements.

Cognitive-behavioral therapy and interpersonal therapy are among the best-researched methods for mild to moderate postpartum depression, and they do not carry the side effects associated with medications. In Poland, access is through a referral within public services or through a private practice.

Pharmacotherapy is an option that is not excluded by breastfeeding. The choice of medication, assessment of its compatibility with lactation, and supervision of treatment belong to a psychiatrist, preferably with perinatal experience. Abandoning treatment for depression "for the child's sake" is a decision that usually harms both, as untreated maternal depression affects care and bonding.

The third pillar is support in daily life: the presence of loved ones, a division of responsibilities allowing the mother to sleep, and contact with other women at the same stage of life. A list of foundations and organizations that we could not confirm as providing support for mothers with postpartum depression in Poland was previously here, so we removed it. Current addresses are known by the community midwife and the family doctor, and it is easiest to start from them.

Is there a situation in which CBD can be considered after childbirth?

Yes, but it is narrow and clearly defined. A woman who has finished breastfeeding no longer exposes her child through milk, so the main source of uncertainty disappears. Questions about her own situation remain.

Even then, cannabidiol is not a treatment for postpartum depression, neither first-line nor second-line. It is at most an adjunct after breastfeeding has ended, in cases of mild symptoms and under medical supervision, alongside psychotherapy, not as a substitute. EFSA excludes from safety assessment individuals taking medications, so when undergoing concurrent antidepressant treatment, a conversation with a doctor precedes everything else. We have gathered broader data on pregnancy and lactation in the text CBD and pregnancy and breastfeeding.

When thoughts of self-harm or harming the child arise, there is no room for considerations about supplements. The emergency number is 112. Support in a mental health crisis is provided by the Crisis Helpline at 116 123, operated by the Institute of Health Psychology and intended for adults in emotional crisis. The previous version of this article described this number as a helpline for women, which does not reflect its intended purpose.

There is one more situation worth stating clearly. Some women turn to cannabidiol not because they believe in its effectiveness, but because it is easier to buy oil than to schedule an appointment with a psychiatrist, and a supplement does not carry the label of a mental illness. This instinct is understandable and can itself be a signal: if you are thinking about CBD for postpartum symptoms, it means you need support. The support worth seeking has research backing, which cannabidiol does not have for this indication.

What does neurobiology say about CBD and mood?

Interest in cannabidiol in depression has biological foundations, but it does not translate into clinical evidence in this specific population. The endocannabinoid system is involved in mood regulation, stress reactivity, and neuroplasticity, and postpartum depression is associated, among other things, with dysregulation of the hypothalamic-pituitary-adrenal axis.

The most frequently cited clinical study is Shannon i wsp. (The Permanente Journal, 2019). It is a retrospective review of psychiatric outpatient records, ultimately involving 72 adult patients presenting with anxiety or poor sleep quality. Anxiety scores decreased in the first month for 57 individuals, or 79.2%, and remained at a lower level. Sleep outcomes improved for 48 individuals, or 66.7%, but fluctuated over time. The authors conclude that controlled studies are needed.

Three caveats must be placed alongside these numbers. The review of records does not have a control group, so it does not account for the placebo effect or natural course. The subjects were not postpartum women. Cannabidiol was administered as an adjunct to existing treatment, not as a replacement. The identifier that was previously here actually led to a completely different work, a review of cannabidiol in anxiety disorders from 2020.

Biological validity is therefore not a recommendation. We write more about the depressive thread in the texts CBD a leczenie depresji and Depresja i konopie.

What risk factors for postpartum depression can be detected earlier?

Postpartum depression rarely comes without warning, and some factors can be recognized even during pregnancy. Knowledge of them can be more practical than searching for a supplement, as it leads to specific actions before symptoms appear.

The strongest single factor is a previous episode of depression or anxiety disorder. Other factors include weak support from a partner and loved ones, difficult living conditions, perinatal complications, and chronic sleep deprivation resulting from colic or feeding problems. A separate factor is the lack of a plan for who will realistically help in the first weeks. We removed the previously provided risk multiple from this place, as it did not have a specified source.

A woman with a history of depression should be under careful observation and have a plan of action established before childbirth, rather than waiting for symptoms. It is worth starting this conversation with the person overseeing the pregnancy, as they will guide further and know the available pathways in the area.

The plan before childbirth does not have to be complicated. It is enough to establish who will take over night feedings once or twice a week so that the mother can sleep for a longer stretch, and who will call for help if symptoms arise. A pre-arranged contact with a psychologist or psychiatrist saves weeks of searching at a time when there is no strength left for searching. This is an intervention without clinical studies and without cost, and it takes away two of postpartum depression's strongest allies: insomnia and isolation.

How to talk to a doctor about CBD after childbirth?

Opening up without beating around the bush, because silence is the only real risk here. A doctor who does not know what the patient is taking cannot assess interactions or plan treatment.

The fear of judgment is understandable and common. However, it is worth remembering that asking about supplements is part of the routine interview, and information about cannabidiol is for the doctor a piece of information about a substance affecting the metabolism of other medications, not a moral judgment. EFSA notes that the hepatotoxic potential of cannabidiol in humans primarily manifests when used concurrently with medications, making this conversation practically necessary.

It is worth preparing three questions in advance. Is cannabidiol safe with my current treatment? Can I return to it after breastfeeding? What are my options if I want to start with therapy rather than medication? The answers to each of these depend on the specific situation, which is why they are not found in any article, including this one.

It can also be helpful to bring the product packaging to the appointment. Labels differ in declared cannabidiol content, form, and carrier composition, and for assessing interactions, this is more significant than the brand name. If the product does not have a certificate of analysis, the doctor has nothing to evaluate, and this is also an answer to the question of safety. The conversation lasts a few minutes and usually ends with one of two recommendations: to stop during treatment or to revisit the topic after breastfeeding.

Frequently Asked Questions

Is CBD safe postpartum?

In a study of the milk of fifty women using marijuana, cannabidiol was detected in five out of 54 samples, with concentrations ranging from 1.32 to 8.56 ng/ml (Bertrand et al., Pediatrics 2018). The six-day persistence referred to THC, not cannabidiol. The study did not cover CBD preparations.

Does CBD pass into breast milk?

Cognitive-behavioral or interpersonal psychotherapy, pharmacotherapy tailored by a psychiatrist, and support in daily care. Breastfeeding does not exclude pharmacological treatment, and the choice of a lactation-compatible medication is up to the doctor. In cases of mild severity, psychotherapy may be the first-line treatment.

How to treat postpartum depression without CBD?

Can CBD harm an infant?

There are no studies measuring this, which is why caution is advised. EFSA notes neurodevelopmental effects from prenatal exposure in animal models, long-lasting and sex-dependent, and a lack of any studies on the immunotoxicity of cannabidiol.

What is baby blues and how to distinguish it from postpartum depression?

Baby blues is a temporary mood swing in the first days after childbirth, usually resolving within two weeks and not requiring treatment. Postpartum depression lasts longer, involves a loss of joy and difficulty in caring for the child, and requires psychological or psychiatric intervention.

Did studies on CBD and anxiety involve women after childbirth?

No. The most frequently cited study by Shannon et al. 2019 is a retrospective review of the records of 72 adult patients in a psychiatric clinic, without a control group. Anxiety symptoms improved in 79.2% of them, but the authors themselves point out the need for controlled studies.

The first weeks after childbirth involve a dramatic hormonal change compounded by sleep deprivation and new responsibilities. According to the World Health Organization, about 13% of women who have just given birth experience a mental disorder, most often depression. At the same time, the number of social media posts recommending CBD oil as a natural support is increasing. This article raises questions in a different order than those recommendations: first about the safety of the child, then about effectiveness for the mother. The answer to the first question is now clear and stems from the position of the European Food Safety Authority, while the answer to the second is much weaker than the headlines suggest. Along the way, we clarify a few numbers that circulated in the previous version of this text in a distorted form regarding the work it referenced.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use hemp or CBD for therapeutic purposes, consult your doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Opublikowano: 2026-05-28 · Aktualizacja: 2026-08-15